19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Subcutaneous pulsatile glucocorticoid replacement therapy

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          The glucocorticoid hormone cortisol is released in pulses resulting in a complex and dynamic ultradian rhythm of plasma cortisol that underlies the classical circadian rhythm. These oscillating levels are also seen at the level of tissues such as the brain and trigger pulses of gene activation and downstream signalling. Different patterns of glucocorticoid presentation (constant vs pulsatile) result not only in different patterns of gene regulation but also in different neuroendocrine and behavioural responses. Current ‘optimal’ glucocorticoid replacement therapy results in smooth hormone blood levels and does not replicate physiological pulsatile cortisol secretion. Validation of a novel portable pulsatile continuous subcutaneous delivery system in healthy volunteers under dexamethasone and metyrapone suppression. Pulsatile subcutaneous hydrocortisone more closely replicates physiological circadian and ultradian rhythmicity.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation.

          Patients with treated adrenal insufficiency (AI) have increased morbidity and mortality rate. Our goal was to improve outcome by developing a once-daily (OD) oral hydrocortisone dual-release tablet with a more physiological exposure-time cortisol profile. The aim was to compare pharmacokinetics and metabolic outcome between OD and the same daily dose of thrice-daily (TID) dose of conventional hydrocortisone tablets. We conducted an open, randomized, two-period, 12-wk crossover multicenter trial with a 24-wk extension at five university hospital centers. The trial enrolled 64 adults with primary AI; 11 had concomitant diabetes mellitus (DM). The same daily dose of hydrocortisone was administered as OD dual-release or TID. We evaluated cortisol pharmacokinetics. Compared with conventional TID, OD provided a sustained serum cortisol profile 0-4 h after the morning intake and reduced the late afternoon and the 24-h cortisol exposure. The mean weight (difference = -0.7 kg, P = 0.005), systolic blood pressure (difference = -5.5 mm Hg, P = 0.0001) and diastolic blood pressure (difference: -2.3 mm Hg; P = 0.03), and glycated hemoglobin (absolute difference = -0.1%, P = 0.0006) were all reduced after OD compared with TID at 12 wk. Compared with TID, a reduction in glycated hemoglobin by 0.6% was observed in patients with concomitant DM during OD (P = 0.004). The OD dual-release tablet provided a more circadian-based serum cortisol profile. Reduced body weight, reduced blood pressure, and improved glucose metabolism were observed during OD treatment. In particular, glucose metabolism improved in patients with concomitant DM.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis.

            To investigate daily cortisol production and clearance rates in a group (n = 18) of normal unstressed pubertal males, we applied deconvolution analysis to serum cortisol concentrations obtained every 20 min for 24 h. Subject-specific characterization of adrenocortical secretory episodes, cortisol production rate, and serum hormone half-life for nine early pubertal (Tanner I or II; early) and nine late pubertal (Tanner IV or V; late) subjects was undertaken to assess potential roles of sexual maturation and changing gonadal steroid hormone concentrations on glucocorticoid physiology. The estimated cortisol production rate for the early group [16.8 +/- 1.3 mumol/m2 x day (6.1 +/- 0.4 mg/m2 x day)] was indistinguishable from that of the late subjects [14.8 +/- 1.4 mumol/m2 x day (5.3 +/- 0.5 mg/m2 x day)]. No differences were observed between the two pubertal groups in the secretory burst frequency and half-duration, mass of cortisol released per secretory episode, average maximal rate of hormone secretion, and serum cortisol half-life. A significant diurnal pattern of cortisol secretion was observed for all subjects manifest by nyctohemeral variations in the frequency of adrenocortical secretory bursts, the amplitude (maximal rate of cortisol secretion) and the mass of cortisol released per secretory episode. Maximum serum hormone concentrations occurred between 0706 and 1114 h. We conclude that in normal pubertal males: 1) cortisol production rates as estimated by deconvolution analysis are in agreement with other recent independent isotopic estimates, but are lower than many previous estimates; 2) the rise in serum gonadal steroid hormone levels is unassociated with alterations in the production rate or metabolic clearance of cortisol; and 3) increased secretory burst frequency, increased amplitude (maximal rate of cortisol secretion attained within each secretory event), and increased mass of cortisol released per adrenocortical secretory episode give rise to the normal diurnal rhythm of circulating cortisol.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy.

              Patients with adrenal insufficiency need lifelong glucocorticoid replacement, but many suffer from poor quality of life, and overall there is increased mortality. Moreover, it appears that use of glucocorticoids at the higher end of the replacement dose range is associated with increased risk for cardiovascular and metabolic bone disease. These data highlight some of the inadequacies of current regimes. The cortisol production rate is estimated to be equivalent to 5.7-7.4 mg/m(2) per day, and a major difficulty for replacement regimes is the inability to match the distinct circadian rhythm of circulating cortisol levels, which are low at the time of sleep onset, rise between 0200 and 0400 h, peaking just after waking and then fall during the day. Another issue is that current dose equivalents of glucocorticoids used for replacement are based on anti-inflammatory potency, and few data exist as to doses needed for equivalent cardiovascular and bone effects. Weight-adjusted, thrice-daily dosing using hydrocortisone (HC) reduces glucocorticoid overexposure and represents the most refined regime for current oral therapy, but does not replicate the normal cortisol rhythm. Recently, proof-of-concept studies have shown that more physiological circadian glucocorticoid therapy using HC infusions and newly developed oral formulations of HC have the potential for better biochemical control in patients with adrenal insufficiency. Whether such physiological replacement will have an impact on the complications seen in patients with adrenal insufficiency will need to be analysed in future clinical trials.
                Bookmark

                Author and article information

                Journal
                Clin Endocrinol (Oxf)
                Clin. Endocrinol. (Oxf)
                cen
                Clinical Endocrinology
                BlackWell Publishing Ltd (Oxford, UK )
                0300-0664
                1365-2265
                January 2014
                01 January 2014
                : 81
                : 2
                : 289-293
                Affiliations
                [* ]Henry Wellcome Laboratories for Integrative Neurosciences and Endocrinology, Dorothy Hodgkin Building, University of Bristol Bristol, UK
                []School of experimental psychology, University of Bristol Bristol, UK
                []Department of Clinical Biochemistry, UHBristol Bristol, UK
                Author notes
                Correspondence: Georgina M Russell, HWLINE, DHB, University of Bristol, Whitson St, Bristol, BS1 3NY, UK. Tel.: (0)117 331 3123; Fax: (0)117 331 3169; E-mail: georgina.russell@ 123456bristol.ac.uk
                Article
                10.1111/cen.12470
                4231230
                24735400
                a0170546-3905-499a-b12b-0a912daf99b6
                © 2014 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 26 March 2014
                : 10 April 2014
                : 11 April 2014
                Categories
                Original Articles

                Endocrinology & Diabetes
                Endocrinology & Diabetes

                Comments

                Comment on this article